The study appeared in online medical journal Cureus on 31 August.
The large study was conducted by Flávio A. Cadegiani, MD, MSc, PhD. Cadegiani is a board-certified endocrinologist with a master’s degree and doctorate degree in clinical endocrinology.
The study was conducted on a strictly controlled population of 88,012 people from the city of Itajaí in Brazil.
Individuals who used ivermectin as prophylaxis or took the medication before being infected by COVID experienced significant reductions in death and hospitalization.
According to the study, those who took ivermectin regularly had a 92% reduction in their COVID death risk compared to non-users and 84% less than irregular users.
Non-use of ivermectin was associated with a 12.5-fold increase in mortality rate and a seven-fold increased risk of dying from COVID-19 compared to the regular use of ivermectin.
An observational study with the size and level of analysis as ours is hardly achieved and infeasible to be conducted as a randomized clinical trial. Conclusions are hard to be refuted. Data is data, regardless of your beliefs. https://t.co/QeHhHxm945
— Flavio A. Cadegiani, MD, MSc, Ph.D. (@FlavioCadegiani) September 1, 2022
— Jamie Sale (@JamieSale) September 3, 2022